Igor Ðan, B. Petrovic, M. Erak, S. Lučić, I. Nikolic, M. Petrović, Vladimir Ðan
{"title":"Influence of FDG/PET CT image registration and fusion on the anal canal carcinoma target volume delineation","authors":"Igor Ðan, B. Petrovic, M. Erak, S. Lučić, I. Nikolic, M. Petrović, Vladimir Ðan","doi":"10.2298/AOO1304143D","DOIUrl":"https://doi.org/10.2298/AOO1304143D","url":null,"abstract":"","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Ilinčić, Z. Stošić, V. Čabarkapa, R. Žeravica, R. Mijović
{"title":"Accurate assessment of renal function prior and after peptide receptor radionuclide therapy","authors":"B. Ilinčić, Z. Stošić, V. Čabarkapa, R. Žeravica, R. Mijović","doi":"10.2298/aoo1304146i","DOIUrl":"https://doi.org/10.2298/aoo1304146i","url":null,"abstract":"","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Since its introduction into clinical medicine 50 years ago, the radionuclide bone scan has played a key role in diagnosing a variety of osseous disorders; particularly metastatic disease. Using small diagnostic doses of Strontium-85 in the 1960’s, it was rapidly established that the study was much more sensitive than skeletal radiographs. The introduction of Technetium-99m phosphate agents in the early 1970’s, offered greatly improved resolution. Whole body imaging became the standard procedure. Interestingly, the positron-emitter, Fluorine 18-sodium fluoride was used by some investigators with the rectilinear scanner. Very recently, this radiotracer has been re-introduced and is witnessing considerable growth using modern PET/CT instrumentation. The cortical bone tracers, 99mTc-MDP and 18F-Fluoride assess osteoblastic response to the invading lesion. In the study of metastatic disease, it is superb for sclerotic blastic lesions. Although it detects most lytic lesions, many can be missed. This is due to a lack of osteoblastic response. The tumor may be slow growing, such as myeloma or conversely very rapidly growing and destructive, such as lung or kidney metastases. In these lesions, 18F-FDG is superior because it is concentrating in the tumor cells and does not depend on osteoblastic response to the tumor. In their early cause, many lytic lesions may be confined to the medullary portion of bone and not yet involve the cortex. Comparative studies of PET and CT have clearly shown the superior sensitivity of FDG in detecting metastatic bone lesions.
{"title":"Bone: From planar imaging to SPECT & PET/CT","authors":"J. Mihailovic, L. Freeman","doi":"10.2298/AOO1204117M","DOIUrl":"https://doi.org/10.2298/AOO1204117M","url":null,"abstract":"Since its introduction into clinical medicine 50 years ago, the radionuclide \u0000 bone scan has played a key role in diagnosing a variety of osseous disorders; \u0000 particularly metastatic disease. Using small diagnostic doses of Strontium-85 \u0000 in the 1960’s, it was rapidly established that the study was much more \u0000 sensitive than skeletal radiographs. The introduction of Technetium-99m \u0000 phosphate agents in the early 1970’s, offered greatly improved resolution. \u0000 Whole body imaging became the standard procedure. Interestingly, the \u0000 positron-emitter, Fluorine 18-sodium fluoride was used by some investigators \u0000 with the rectilinear scanner. Very recently, this radiotracer has been \u0000 re-introduced and is witnessing considerable growth using modern PET/CT \u0000 instrumentation. The cortical bone tracers, 99mTc-MDP and 18F-Fluoride assess \u0000 osteoblastic response to the invading lesion. In the study of metastatic \u0000 disease, it is superb for sclerotic blastic lesions. Although it detects most \u0000 lytic lesions, many can be missed. This is due to a lack of osteoblastic \u0000 response. The tumor may be slow growing, such as myeloma or conversely very \u0000 rapidly growing and destructive, such as lung or kidney metastases. In these \u0000 lesions, 18F-FDG is superior because it is concentrating in the tumor cells \u0000 and does not depend on osteoblastic response to the tumor. In their early \u0000 cause, many lytic lesions may be confined to the medullary portion of bone \u0000 and not yet involve the cortex. Comparative studies of PET and CT have \u0000 clearly shown the superior sensitivity of FDG in detecting metastatic bone \u0000 lesions.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1204117M","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68401896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
2 SUMMARY PET/CT has proven to be extremely useful in studying neoplasms of the colon and esophagus. It has been less promising for lesions of the stomach, pancreas and hepatobiliary tract. Colorectal cancer is the third most common non-cutaneous cancer representing 13% of all malignancies. The use of colonoscopy has significantly contributed to the earlier detection and higher cure rate. PET/CT is not a screening procedure. It is very good for staging, recurrence detection and monitor- ing therapeutic interventions. It is excellent for detecting distant metastases, e.g. liver lesions, but is less accurate for detecting nodal involvement. The CT portion of the study enhances certainty of lesion localization and characterization. Esophageal cancer is less common in the U.S. in that it represents 7% of G-I cancers, but only 1% of all cancers. The major problem is that often it is advanced to Stages III or IV before it comes to clinical recognition. A 5-year survival has been improved from 3% to 10% by the use of induction chemoradiotherapy. PET has proven useful in staging and deter- mining resectability, monitoring response to therapy, radiotherapy treatment planning and distinguishing between post- op scar and residual or recurrent disease on CT. Gastric cancer results have been more variable. The intestinal (tubular variety) shows better uptake than the non-intestinal (signet ring cell) variety because of the greater mucous content of the latter which is associated with more false negatives. FDG uptake in pancreatic cancer is also variable. Attempts at distinguishing carcinoma from pancreatitis have been limited. When lesions do show uptake, PET/CT has been helpful in monitoring therapeutic interventions. Hepatocellular cancer demonstrates significant FDG uptake in only 50-70% of cases. Cholangio carcinomas; particularly the peripheral variety, do show significant FDG uptake.
{"title":"Positron emission tomography in neoplasms of the digestive system","authors":"J. Mihailovic, L. Freeman","doi":"10.2298/AOO1204086M","DOIUrl":"https://doi.org/10.2298/AOO1204086M","url":null,"abstract":"2 SUMMARY PET/CT has proven to be extremely useful in studying neoplasms of the colon and esophagus. It has been less promising for lesions of the stomach, pancreas and hepatobiliary tract. Colorectal cancer is the third most common non-cutaneous cancer representing 13% of all malignancies. The use of colonoscopy has significantly contributed to the earlier detection and higher cure rate. PET/CT is not a screening procedure. It is very good for staging, recurrence detection and monitor- ing therapeutic interventions. It is excellent for detecting distant metastases, e.g. liver lesions, but is less accurate for detecting nodal involvement. The CT portion of the study enhances certainty of lesion localization and characterization. Esophageal cancer is less common in the U.S. in that it represents 7% of G-I cancers, but only 1% of all cancers. The major problem is that often it is advanced to Stages III or IV before it comes to clinical recognition. A 5-year survival has been improved from 3% to 10% by the use of induction chemoradiotherapy. PET has proven useful in staging and deter- mining resectability, monitoring response to therapy, radiotherapy treatment planning and distinguishing between post- op scar and residual or recurrent disease on CT. Gastric cancer results have been more variable. The intestinal (tubular variety) shows better uptake than the non-intestinal (signet ring cell) variety because of the greater mucous content of the latter which is associated with more false negatives. FDG uptake in pancreatic cancer is also variable. Attempts at distinguishing carcinoma from pancreatitis have been limited. When lesions do show uptake, PET/CT has been helpful in monitoring therapeutic interventions. Hepatocellular cancer demonstrates significant FDG uptake in only 50-70% of cases. Cholangio carcinomas; particularly the peripheral variety, do show significant FDG uptake.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1204086M","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68401755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
th 2009 to February the 6 th 2012) with PRRT in Nuclear Medicine Center, Clinical Center Kragujevac. There were carci- noids in 8 cases (6pts had intestinal and 2pts had lung carcinoid), medullary thyroid carcinoma in 5 cases, pancreatic carcinoma in 3 cases, paraganlioma in 2 cases, pheochromocytoma in 2 cases and in 7 cases primary tumors were not detected. We used 56 doses of different kinds of radiopharmaceuticals: 32 doses of 90Y-DOTATOC, 12 doses of 177Lu-DOTATATE, and 12 doses combining the 90Y-DODTATOC and 177Lu-DOTATATE. The PRRT was given in cycles: 12 pts received one cycle, 9 pts two cycles, 4 pts three cycles, 1 patient 4cycles and 2 pts five cycles of PRRT. The radioactivity was 3.2-7.40 GBq per cycle, and intervals between cycles ranged from 6 to 8 weeks. Results: The response to PRRT was assessed by morphological imaging (MSCT and MRI) as well as by tumor marker follow up (CgA, 5-HIAA, catecholamines, CT and CEA). Seven pts (25.9%) had partial response (PR), 17 pts (63.0%) had stable disease (SD), and 3 pts (11.1%) had progressive disease (PD). None of our patients had complete response (CR). All patients received PRRT under renal protection with amino acid infusions. In spite of this precaution, two patients with previously diagnosed diabetes mellitus suffered from serious deterioration of renal function after PRRT. Conclusion: The efficacy and safety of PRRT observed in our case series was in accordance with previously published
{"title":"Peptide receptor radionuclide therapy of neuroendocrine tumors: Case series","authors":"M. Matović","doi":"10.2298/AOO1204143M","DOIUrl":"https://doi.org/10.2298/AOO1204143M","url":null,"abstract":"th 2009 to February the 6 th 2012) with PRRT in Nuclear Medicine Center, Clinical Center Kragujevac. There were carci- noids in 8 cases (6pts had intestinal and 2pts had lung carcinoid), medullary thyroid carcinoma in 5 cases, pancreatic carcinoma in 3 cases, paraganlioma in 2 cases, pheochromocytoma in 2 cases and in 7 cases primary tumors were not detected. We used 56 doses of different kinds of radiopharmaceuticals: 32 doses of 90Y-DOTATOC, 12 doses of 177Lu-DOTATATE, and 12 doses combining the 90Y-DODTATOC and 177Lu-DOTATATE. The PRRT was given in cycles: 12 pts received one cycle, 9 pts two cycles, 4 pts three cycles, 1 patient 4cycles and 2 pts five cycles of PRRT. The radioactivity was 3.2-7.40 GBq per cycle, and intervals between cycles ranged from 6 to 8 weeks. Results: The response to PRRT was assessed by morphological imaging (MSCT and MRI) as well as by tumor marker follow up (CgA, 5-HIAA, catecholamines, CT and CEA). Seven pts (25.9%) had partial response (PR), 17 pts (63.0%) had stable disease (SD), and 3 pts (11.1%) had progressive disease (PD). None of our patients had complete response (CR). All patients received PRRT under renal protection with amino acid infusions. In spite of this precaution, two patients with previously diagnosed diabetes mellitus suffered from serious deterioration of renal function after PRRT. Conclusion: The efficacy and safety of PRRT observed in our case series was in accordance with previously published","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1204143M","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68402042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-01-01DOI: 10.1007/978-3-642-15726-4_3
C. Aparici, A. Avram, Á. Castrejón, R. Dvorak, P. Erba, J. Fettich, José Manuel Cordero García, V. M. P. García, R. Hawkins, M. Hodolič, P. T. Rubio, Youngho Seo, A. M. G. Vicente, J. Woll, K. Wong
{"title":"SPECT/CT for tumour imaging","authors":"C. Aparici, A. Avram, Á. Castrejón, R. Dvorak, P. Erba, J. Fettich, José Manuel Cordero García, V. M. P. García, R. Hawkins, M. Hodolič, P. T. Rubio, Youngho Seo, A. M. G. Vicente, J. Woll, K. Wong","doi":"10.1007/978-3-642-15726-4_3","DOIUrl":"https://doi.org/10.1007/978-3-642-15726-4_3","url":null,"abstract":"","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-3-642-15726-4_3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"51073906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2012-01-01DOI: 10.1007/978-1-4614-4021-5_1
S. Goldsmith
{"title":"Radioimmunotherapy of Lymphoma","authors":"S. Goldsmith","doi":"10.1007/978-1-4614-4021-5_1","DOIUrl":"https://doi.org/10.1007/978-1-4614-4021-5_1","url":null,"abstract":"","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-1-4614-4021-5_1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50978118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The diagnostic imaging procedures that have a role in detection of malignant thyroid tissue are radioiodine (131I) diagnostic whole-body scintigraphy (WBS), neck ultrasound, and CT and MRI for evaluation of the mediastinal area. Despite excellent morphologic characterization of metastatic nodal recurrences, MRI cannot reliably make a differentiation between benign and malignant lymph nodes. Although it detects enlarged metastatic lymph nodes, there are also many small nodal metastases that are usually missed. In one-third of patients with well differentiated thyroid carcinoma, there are carcinomas with dedifferentiated tumor cells: metastatic tissue may not concentrate radioiodine well; thus 131I-WBS is negative despite elevated thyroglobulin (Tg) levels. Although MRI helps in detection of these non-iodine avid metastases, FDG PET/CT can perform more effectively. Due to its high glycolytic rate, changes in glucose transport systems and hexokinase activity, [18F] fluorodeoxyglucose (FDG) accumulates in malignant tissue and is useful for identification of distant metastases in these patients. Iodine positive metastases are often negative with FDG-PET imaging while iodine negative metastases exhibit increased FDG-uptake. If a metastatic lesion is identified by FDG positron emission tomography/ computed tomography (PET/CT), the usual approach is to first send the patient to surgery for removal of neoplastic tissue, if possible. This is followed by re-treatment with 131I therapy after tumor redifferentiation with retinoic acid. In a limited number of patients, iodine negative thyroid cancer may express somatostatin receptors and radiopeptide therapy may be utilized. FDG PET/CT is a hybrid imaging diagnostic tool which helps in detection of non-iodine avid metastases. It has a role in exact localization of recurrences which will assist in the decision to remove the malignant tissue surgically.
{"title":"PET/CT in thyroid carcinoma","authors":"J. Mihailovic","doi":"10.2298/AOO1204112M","DOIUrl":"https://doi.org/10.2298/AOO1204112M","url":null,"abstract":"The diagnostic imaging procedures that have a role in detection of malignant thyroid tissue are radioiodine (131I) diagnostic whole-body scintigraphy (WBS), neck ultrasound, and CT and MRI for evaluation of the mediastinal area. Despite excellent morphologic characterization of metastatic nodal recurrences, MRI cannot reliably make a differentiation between benign and malignant lymph nodes. Although it detects enlarged metastatic lymph nodes, there are also many small nodal metastases that are usually missed. In one-third of patients with well differentiated thyroid carcinoma, there are carcinomas with dedifferentiated tumor cells: metastatic tissue may not concentrate radioiodine well; thus 131I-WBS is negative despite elevated thyroglobulin (Tg) levels. Although MRI helps in detection of these non-iodine avid metastases, FDG PET/CT can perform more effectively. Due to its high glycolytic rate, changes in glucose transport systems and hexokinase activity, [18F] fluorodeoxyglucose (FDG) accumulates in malignant tissue and is useful for identification of distant metastases in these patients. Iodine positive metastases are often negative with FDG-PET imaging while iodine negative metastases exhibit increased FDG-uptake. If a metastatic lesion is identified by FDG positron emission tomography/ computed tomography (PET/CT), the usual approach is to first send the patient to surgery for removal of neoplastic tissue, if possible. This is followed by re-treatment with 131I therapy after tumor redifferentiation with retinoic acid. In a limited number of patients, iodine negative thyroid cancer may express somatostatin receptors and radiopeptide therapy may be utilized. FDG PET/CT is a hybrid imaging diagnostic tool which helps in detection of non-iodine avid metastases. It has a role in exact localization of recurrences which will assist in the decision to remove the malignant tissue surgically.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1204112M","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68401871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Remission during sunitinib (a multikinase inhibitor and antiangiogenic drug) treatment correlates with appearance of macrocytosis. There are some suggestions that bevacizumab, an antiangiogenic drug, may result in macrocytosis as well. There are no published data available on the influence of bevacizumab on macrocytosis. This paper attempted to answer the question: does bevacizumab induce macrocytosis being a predictor of the response? Methods: Between August 2008 and August 2011, 53 patients (29 male and 24 female) were treated with bevacizumab in the combination with chemotherapy at the Oncological Department, University Hospital in Krakow, Poland. Efficacy of bevacizumab was assessed on the basis of the computer tomography scans performed every 3 months within the period of 12 months. Concurrently, mean corpuscular volume (MCV) was evaluated and correlated to the response of the treatment. Results: The percentage increase of MCV compared to baseline at 3, 6, 9 and 12 months was 3.7%, 9.2%, 8.7% and 11.8% respectively. The mean value of baseline MCV was 85.3 fl. The mean value of MCV at 3, 6, 9 and 12 months was 90.5 fl, 93 fl, 91.8 fl and 93.1 fl respectively. Macrocytosis did not occur in our study but an increase of MCV was observed within bevacizumab therapy. It was closely related to the response of the treatment. It seems that an increase of MCV can be a predictive agent of bevacizumab response. Conclusion: Bevacizumab does not induce macrocytosis. Increased MCV after treatment with bevacizumab is related to the treatment response. MCV can be a predictor of the response during bevacizumab treatment. A small number of the observed patients requires further investigations.
{"title":"Increased mean corpuscular volume as a predictor of response during bevacizumab treatment","authors":"Lidia Aneta Zygulska, K. Krzemieniecki","doi":"10.2298/AOO1202015Z","DOIUrl":"https://doi.org/10.2298/AOO1202015Z","url":null,"abstract":"Background: Remission during sunitinib (a multikinase inhibitor and antiangiogenic drug) treatment correlates with appearance of macrocytosis. There are some suggestions that bevacizumab, an antiangiogenic drug, may result in macrocytosis as well. There are no published data available on the influence of bevacizumab on macrocytosis. This paper attempted to answer the question: does bevacizumab induce macrocytosis being a predictor of the response? Methods: Between August 2008 and August 2011, 53 patients (29 male and 24 female) were treated with bevacizumab in the combination with chemotherapy at the Oncological Department, University Hospital in Krakow, Poland. Efficacy of bevacizumab was assessed on the basis of the computer tomography scans performed every 3 months within the period of 12 months. Concurrently, mean corpuscular volume (MCV) was evaluated and correlated to the response of the treatment. Results: The percentage increase of MCV compared to baseline at 3, 6, 9 and 12 months was 3.7%, 9.2%, 8.7% and 11.8% respectively. The mean value of baseline MCV was 85.3 fl. The mean value of MCV at 3, 6, 9 and 12 months was 90.5 fl, 93 fl, 91.8 fl and 93.1 fl respectively. Macrocytosis did not occur in our study but an increase of MCV was observed within bevacizumab therapy. It was closely related to the response of the treatment. It seems that an increase of MCV can be a predictive agent of bevacizumab response. Conclusion: Bevacizumab does not induce macrocytosis. Increased MCV after treatment with bevacizumab is related to the treatment response. MCV can be a predictor of the response during bevacizumab treatment. A small number of the observed patients requires further investigations.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1202015Z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68401155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Tegeltija, A. Lovrenski, Milana Panjković, Ž. Eri, I. Klem
Testicular fibroma is a rare benign tumor of gradual growth, usually in the third and fourth decade, in the form of a hypoechogenous nodule with clear boundaries and is usually not accompanied by hormonal abnormalities. Metastasis and recurrence of disease were not noted. A 40-year-old male saught medical attention due to pain in the lower back that spread to the pubic bones and the groin. During physical examination, a painless nodule with clear boundaries was palpated in the right testicle, and the ultrasonographic examination revealed hypoechogenic zone with vague boundaries of about 10 mm in diameter. Standard biochemical analyses of blood and urine tests and tumor markers (CEA, CA 125, CA 19-9, AFP and βHCG) were within the physiological limit. Histopathologic analysis set a diagnosis of testicular fibroma. The absence of sex cords in the tumor tissue made it possible to diagnose the patient using standard staining methods, but in cases where these elements can be histologically verified, immunohistochemical analysis should be introduced into a routine diagnostic algorithm.
{"title":"Testicular (gonadal stromal) fibroma: case report","authors":"D. Tegeltija, A. Lovrenski, Milana Panjković, Ž. Eri, I. Klem","doi":"10.2298/AOO1202026T","DOIUrl":"https://doi.org/10.2298/AOO1202026T","url":null,"abstract":"Testicular fibroma is a rare benign tumor of gradual growth, usually in the third and fourth decade, in the form of a hypoechogenous nodule with clear boundaries and is usually not accompanied by hormonal abnormalities. Metastasis and recurrence of disease were not noted. A 40-year-old male saught medical attention due to pain in the lower back that spread to the pubic bones and the groin. During physical examination, a painless nodule with clear boundaries was palpated in the right testicle, and the ultrasonographic examination revealed hypoechogenic zone with vague boundaries of about 10 mm in diameter. Standard biochemical analyses of blood and urine tests and tumor markers (CEA, CA 125, CA 19-9, AFP and βHCG) were within the physiological limit. Histopathologic analysis set a diagnosis of testicular fibroma. The absence of sex cords in the tumor tissue made it possible to diagnose the patient using standard staining methods, but in cases where these elements can be histologically verified, immunohistochemical analysis should be introduced into a routine diagnostic algorithm.","PeriodicalId":35645,"journal":{"name":"Archive of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2298/AOO1202026T","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68401240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：